AIMS/HYPOTHESIS: This study aimed to determine whether protein kinase C (PKC) delta plays a role in the glucose intolerance caused by a high-fat diet, and whether it could compensate for loss of PKCepsilon in the generation of insulin resistance in skeletal muscle. METHODS: Prkcd (-/-), Prkce (-/-) and wild-type mice were fed high-fat diets and subjected to glucose tolerance tests. Blood glucose levels and insulin responses were determined during the tests. Insulin signalling in liver and muscle was assessed after acute in vivo insulin stimulation by immunoblotting with phospho-specific antibodies. Activation of PKC isoforms in muscle from Prkce (-/-) mice was assessed by determining intracellular distribution. Tissues and plasma were assayed for triacylglycerol accumulation, and hepatic production of lipogenic enzymes was determined by immunoblotting. RESULTS: Both Prkcd (-/-) and Prkce (-/-) mice were protected against high-fat-diet-induced glucose intolerance. In Prkce (-/-) mice this was mediated through enhanced insulin availability, while in Prkcd (-/-) mice the reversal occurred in the absence of elevated insulin. Neither the high-fat diet nor Prkcd deletion affected maximal insulin signalling. The activation of PKCdelta in muscle from fat-fed mice was enhanced by Prkce deletion. PKCdelta-deficient mice exhibited reduced liver triacylglycerol accumulation and diminished production of lipogenic enzymes. CONCLUSIONS/ INTERPRETATION: Deletion of genes encoding isoforms of PKC can improve glucose intolerance, either by enhancing insulin availability in the case of Prkce, or by reducing lipid accumulation in the case of Prkcd. The absence of PKCepsilon in muscle may be compensated by increased activation of PKCdelta in fat-fed mice, suggesting that an additional role for PKCepsilon in this tissue is masked.
AIMS/HYPOTHESIS: This study aimed to determine whether protein kinase C (PKC) delta plays a role in the glucose intolerance caused by a high-fat diet, and whether it could compensate for loss of PKCepsilon in the generation of insulin resistance in skeletal muscle. METHODS:Prkcd (-/-), Prkce (-/-) and wild-type mice were fed high-fat diets and subjected to glucose tolerance tests. Blood glucose levels and insulin responses were determined during the tests. Insulin signalling in liver and muscle was assessed after acute in vivo insulin stimulation by immunoblotting with phospho-specific antibodies. Activation of PKC isoforms in muscle from Prkce (-/-) mice was assessed by determining intracellular distribution. Tissues and plasma were assayed for triacylglycerol accumulation, and hepatic production of lipogenic enzymes was determined by immunoblotting. RESULTS: Both Prkcd (-/-) and Prkce (-/-) mice were protected against high-fat-diet-induced glucose intolerance. In Prkce (-/-) mice this was mediated through enhanced insulin availability, while in Prkcd (-/-) mice the reversal occurred in the absence of elevated insulin. Neither the high-fat diet nor Prkcd deletion affected maximal insulin signalling. The activation of PKCdelta in muscle from fat-fed mice was enhanced by Prkce deletion. PKCdelta-deficientmice exhibited reduced liver triacylglycerol accumulation and diminished production of lipogenic enzymes. CONCLUSIONS/ INTERPRETATION: Deletion of genes encoding isoforms of PKC can improve glucose intolerance, either by enhancing insulin availability in the case of Prkce, or by reducing lipid accumulation in the case of Prkcd. The absence of PKCepsilon in muscle may be compensated by increased activation of PKCdelta in fat-fed mice, suggesting that an additional role for PKCepsilon in this tissue is masked.
Authors: Zhanguo Gao; Zhong Wang; Xiaoying Zhang; Andrew A Butler; Aamir Zuberi; Barbara Gawronska-Kozak; Michael Lefevre; David York; Eric Ravussin; Hans-Rudolf Berthoud; Owen McGuinness; William T Cefalu; Jianping Ye Journal: Am J Physiol Endocrinol Metab Date: 2006-08-08 Impact factor: 4.310
Authors: M Leitges; M Mayr; U Braun; U Mayr; C Li; G Pfister; N Ghaffari-Tabrizi; G Baier; Y Hu; Q Xu Journal: J Clin Invest Date: 2001-11 Impact factor: 14.808
Authors: C Schmitz-Peiffer; C L Browne; N D Oakes; A Watkinson; D J Chisholm; E W Kraegen; T J Biden Journal: Diabetes Date: 1997-02 Impact factor: 9.461
Authors: Varman T Samuel; Zhen-Xiang Liu; Amy Wang; Sara A Beddow; John G Geisler; Mario Kahn; Xian-man Zhang; Brett P Monia; Sanjay Bhanot; Gerald I Shulman Journal: J Clin Invest Date: 2007-02-22 Impact factor: 14.808
Authors: Jason K Kim; Jonathan J Fillmore; Mary Jean Sunshine; Bjoern Albrecht; Takamasa Higashimori; Dong-Wook Kim; Zhen-Xiang Liu; Timothy J Soos; Gary W Cline; William R O'Brien; Dan R Littman; Gerald I Shulman Journal: J Clin Invest Date: 2004-09 Impact factor: 14.808
Authors: Michael W Greene; Christine M Burrington; Mary S Ruhoff; Andrew K Johnson; Tepsiri Chongkrairatanakul; Atipon Kangwanpornsiri Journal: J Biol Chem Date: 2010-10-22 Impact factor: 5.157
Authors: Olivier Bezy; Thien T Tran; Jussi Pihlajamäki; Ryo Suzuki; Brice Emanuelli; Jonathan Winnay; Marcelo A Mori; Joel Haas; Sudha B Biddinger; Michael Leitges; Allison B Goldfine; Mary Elizabeth Patti; George L King; C Ronald Kahn Journal: J Clin Invest Date: 2011-05-16 Impact factor: 14.808
Authors: K Raddatz; N Turner; G Frangioudakis; B M Liao; D J Pedersen; J Cantley; D Wilks; E Preston; B D Hegarty; M Leitges; M J Raftery; T J Biden; C Schmitz-Peiffer Journal: Diabetologia Date: 2011-02-24 Impact factor: 10.122
Authors: Benjamin T Bikman; Donghai Zheng; Daniel A Kane; Ethan J Anderson; Tracey L Woodlief; Jesse W Price; G Lynis Dohm; P Darrell Neufer; Ronald N Cortright Journal: J Obes Date: 2010-01-14